Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, USA.
J Clin Invest. 2013 Apr;123(4):1750-62. doi: 10.1172/JCI66432. Epub 2013 Mar 8.
Type 2 diabetes (T2D) has emerged as a major threat to human health in most parts of the world. Therapeutic strategies aimed at improving pancreatic β cell function are predicted to prove beneficial for the treatment of T2D. In the present study, we demonstrate that drug-mediated, chronic, and selective activation of β cell G(q) signaling greatly improve β cell function and glucose homeostasis in mice. These beneficial metabolic effects were accompanied by the enhanced expression of many genes critical for β cell function, maintenance, and differentiation. By employing a combination of in vivo and in vitro approaches, we identified a novel β cell pathway through which receptor-activated G(q) leads to the sequential activation of ERK1/2 and IRS2 signaling, thus triggering a series of events that greatly improve β cell function. Importantly, we found that chronic stimulation of a designer G(q)-coupled receptor selectively expressed in β cells prevented both streptozotocin-induced diabetes and the metabolic deficits associated with the consumption of a high-fat diet in mice. Since β cells are endowed with numerous receptors that mediate their cellular effects via activation of G(q)-type G proteins, our findings provide a rational basis for the development of novel antidiabetic drugs targeting this class of receptors.
2 型糖尿病(T2D)已成为世界大部分地区人类健康的主要威胁。旨在改善胰岛β细胞功能的治疗策略有望被证明对 T2D 的治疗有益。在本研究中,我们证明了药物介导的、慢性的、选择性的β细胞 G(q)信号转导的激活极大地改善了小鼠的β细胞功能和葡萄糖稳态。这些有益的代谢效应伴随着许多对β细胞功能、维持和分化至关重要的基因的表达增强。通过采用体内和体外相结合的方法,我们确定了一条新的β细胞途径,通过该途径,受体激活的 G(q)导致 ERK1/2 和 IRS2 信号的顺序激活,从而引发一系列大大改善β细胞功能的事件。重要的是,我们发现慢性刺激选择性表达在β细胞中的设计 G(q)偶联受体可预防链脲佐菌素诱导的糖尿病以及高脂肪饮食引起的代谢缺陷。由于β细胞具有许多通过激活 G(q)型 G 蛋白介导其细胞效应的受体,我们的发现为开发针对这类受体的新型抗糖尿病药物提供了合理的依据。